{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:36:07Z","timestamp":1791275767472,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PEST \u2013 C\/SAU\/LAOOO1\/2011"],"award-info":[{"award-number":["PEST \u2013 C\/SAU\/LAOOO1\/2011"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PEst-C\/SAU\/LA0001\/2013"],"award-info":[{"award-number":["PEst-C\/SAU\/LA0001\/2013"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["94728"],"award-info":[{"award-number":["94728"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["PTDC\/SAU-OSM\/104124\/2008"],"award-info":[{"award-number":["PTDC\/SAU-OSM\/104124\/2008"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["SFRH\/BD\/63962\/2009"],"award-info":[{"award-number":["SFRH\/BD\/63962\/2009"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004494","name":"Nature Conservancy of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004494","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.bcp.2014.01.020","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T11:30:41Z","timestamp":1390390241000},"page":"216-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model"],"prefix":"10.1016","volume":"88","author":[{"given":"A.","family":"Fuhrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PC.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sereno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.O.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2014.01.020_bib0005","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0031-3955(03)00121-4","article-title":"Current immunosuppressive agents: efficacy, side effects, and utilization","volume":"50","author":"Smith","year":"2003","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.bcp.2014.01.020_bib0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1432-2277.2008.00800.x","article-title":"New-onset diabetes mellitus after solid organ transplantation","volume":"22","author":"Bodziak","year":"2009","journal-title":"Traspl Int"},{"key":"10.1016\/j.bcp.2014.01.020_bib0015","first-page":"233","article-title":"Predicting, managing and preventing new-onset diabetes after transplantation","volume":"37","author":"Gosmanov","year":"2012","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11255-007-9266-y","article-title":"Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function","volume":"40","author":"Perrea","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11892-009-0047-0","article-title":"Dyslipidemia following kidney transplantation: diagnosis and treatment","volume":"9","author":"Badiou","year":"2009","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.bcp.2014.01.020_bib0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00007890-198111000-00002","article-title":"Cyclosporin A","volume":"32","author":"Morris","year":"1981","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2014.01.020_bib0035","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","article-title":"Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders","volume":"45","author":"Faulds","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2014.01.020_bib0040","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1073\/pnas.89.9.3686","article-title":"Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A","volume":"89","author":"Fruman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bcp.2014.01.020_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-200565020-00001","article-title":"Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?","volume":"65","author":"Egidi","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2014.01.020_bib0050","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2011","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bcp.2014.01.020_bib0055","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2014.01.020_bib0060","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4161\/cc.10.6.14930","article-title":"The integral role of mTOR in lipid metabolism","volume":"10","author":"Soliman","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2014.01.020_bib0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bcp.2014.01.020_bib0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0075","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.tp.0000286095.55685.e9","article-title":"Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia","volume":"84","author":"Ma","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2014.01.020_bib0080","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1440-1797.2008.01052.x","article-title":"Review article: new-onset diabetes after transplantation","volume":"13","author":"Chow","year":"2008","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.bcp.2014.01.020_bib0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.transproceed.2011.01.033","article-title":"Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study","volume":"43","author":"Pankewycz","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bcp.2014.01.020_bib0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1023\/A:1007009723616","article-title":"Insulin resistance in fat cells from obese Zucker rats \u2013 evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4","volume":"206","author":"Carvalho","year":"2000","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.bcp.2014.01.020_bib0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1742-7843.2009.00427.x","article-title":"Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK\/HlJ mice","volume":"105","author":"Chang","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0100","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/j.1476-5381.2011.01716.x","article-title":"Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats","volume":"165","author":"Deblon","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0105","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0110","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1124\/mol.63.6.1289","article-title":"Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice","volume":"63","author":"Oetjen","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1476-5381.2010.01018.x","article-title":"Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells","volume":"62","author":"\u00d8zbay","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/TP.0b013e3181928a1c","article-title":"Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients","volume":"87","author":"Gillard","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2014.01.020_bib0125","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"Houde","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.01.020_bib0130","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1016\/j.transproceed.2011.08.074","article-title":"Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen","volume":"43","author":"Spinelli","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bcp.2014.01.020_bib0135","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/db09-1602","article-title":"Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage","volume":"59","author":"Chakrabarti","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.01.020_bib0140","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2337\/db09-1061","article-title":"Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism","volume":"59","author":"Kumar","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.01.020_bib0145","first-page":"E1087","article-title":"Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2","volume":"277","author":"Wu","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1399-0012.2009.00962.x","article-title":"Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation","volume":"23","author":"Asberg","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bcp.2014.01.020_bib0155","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/0006-2952(92)90202-T","article-title":"In vivo and in vitro effects of cyclosporin A on glucose transport by soleus muscles of mice","volume":"43","author":"Ikeuchi","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0160","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2125.2011.04118.x","article-title":"Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers","volume":"73","author":"\u00d8zbay","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mce.2012.01.024","article-title":"mTOR inhibition with rapamycin causes impaired insulin signaling and glucose uptake in human subcutaneous and omental adipocytes","volume":"355","author":"Pereira","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0170","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1210\/en.2004-1675","article-title":"Insulin receptor substrates-1 and -2 are both depleted but via different mechanisms after down-regulation of glucose transport in rat adipocytes","volume":"146","author":"Renstr\u00f6m","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2014.01.020_bib0175","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1096\/fasebj.13.15.2173","article-title":"Low cellular IRS-1 gene and protein expression predict insulin resistance and NIDDM","volume":"13","author":"Carvalho","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2014.01.020_bib0180","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1096\/fsb2fj000435fje","article-title":"Defficient IRS-1 and Glut4 protein expression in adipocytes from insulin resistant subjects","volume":"15","author":"Carvalho","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2014.01.020_bib0185","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s001250051501","article-title":"Impaired phosphorylation and insulin-stimulated translocation to the plasma membrane of Protein Kinase B\/Akt in adipocytes from type 2 diabetic subjects","volume":"43","author":"Carvalho","year":"2000","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2014.01.020_bib0190","first-page":"S229","article-title":"Cyclosporin A and tacrolimus can reduce GLUT4 at the cell surface via increased endocytosis and this leads to impaired cellular glucose uptake","volume":"55","author":"Pereira","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2014.01.020_bib0195","unstructured":"Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK, et al. Cyclosporine A and tacrolimus reduce cell-surface amount of GLUT4 via increased endocytosis: a potential mechanism for the diabetogenic effects of immunosuppressive agents. Unpublished results."},{"key":"10.1016\/j.bcp.2014.01.020_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","article-title":"Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins","volume":"89","author":"Wood","year":"2003","journal-title":"Br J Nutr"},{"key":"10.1016\/j.bcp.2014.01.020_bib0205","first-page":"4","article-title":"Recent advances in the relationship between obesity, inflammation, and insulin resistance","volume":"17","author":"Bastard","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.bcp.2014.01.020_bib0210","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.mce.2012.10.030","article-title":"The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipocytes","volume":"365","author":"Pereira","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2004.04.010","article-title":"Targets for TNF-alpha-induced lipolysis in human adipocytes","volume":"318","author":"Ryd\u00e9n","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2014.01.020_bib0220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jss.2010.05.035","article-title":"Role of the mTOR pathway in LPS-activated monocytes: influence of hypertonic saline","volume":"171","author":"Schaeffer","year":"2011","journal-title":"J Surg Res"},{"key":"10.1016\/j.bcp.2014.01.020_bib0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.33549\/physiolres.931863","article-title":"Adiponectin inhibits spontaneous and catecholamine-induced lipolysis in human adipocytes of non-obese subjects through AMPK-dependent mechanisms","volume":"60","author":"Wedellov","year":"2011","journal-title":"Physiol Res"},{"key":"10.1016\/j.bcp.2014.01.020_bib0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1152\/advan.00052.2006","article-title":"PGC-1alpha: a key regulator of energy metabolism","volume":"30","author":"Liang","year":"2006","journal-title":"Adv Physiol Educ"},{"key":"10.1016\/j.bcp.2014.01.020_bib0235","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1172\/JCI32054","article-title":"A Foxo\/Notch pathway controls myogenic differentiation and fiber type specification","volume":"117","author":"Kitamura","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2014.01.020_bib0240","doi-asserted-by":"crossref","first-page":"21176","DOI":"10.1074\/jbc.M702039200","article-title":"FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle","volume":"282","author":"Southgate","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.01.020_bib0245","doi-asserted-by":"crossref","first-page":"C188","DOI":"10.1152\/ajpcell.00542.2005","article-title":"Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors","volume":"292","author":"Allen","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1534-5807(02)00401-X","article-title":"The forkhead transcription factor Foxo1 regulates adipocyte differentiation","volume":"4","author":"Nakae","year":"2003","journal-title":"Dev Cell"},{"key":"10.1016\/j.bcp.2014.01.020_bib0255","first-page":"2464","article-title":"Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism","volume":"116","author":"Matsumoto","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2014.01.020_bib0260","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1128\/MCB.19.5.3760","article-title":"ADD1\/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose","volume":"19","author":"Foretz","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bcp.2014.01.020_bib0265","first-page":"617","article-title":"ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome","volume":"55","author":"Iizuka","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2014.01.020_bib0270","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1210\/en.2003-0849","article-title":"Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity","volume":"144","author":"Ruderman","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2014.01.020_bib0275","doi-asserted-by":"crossref","first-page":"41838","DOI":"10.1074\/jbc.M111.245456","article-title":"Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases","volume":"286","author":"Cao","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.01.020_bib0280","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/diabetes.51.1.7","article-title":"Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes","volume":"51","author":"McGarry","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2014.01.020_bib0285","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1172\/JCI118742","article-title":"Mechanism of free fatty acid-induced insulin resistance in humans","volume":"97","author":"Roden","year":"1996","journal-title":"J Clin Invest"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:57:56Z","timestamp":1757768276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0006295214000446"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.01.020","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}